Venus Remedies Limited (VENUSREM) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Venus Remedies Limited ₹1,976, price ₹1,797, upside +10.0%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Venus Remedies Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹147.75 – ₹1,947 · fair‑value band ₹1,310 – ₹2,674 · the ₹1,797 price screens below the ₹1,976 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 1, 2026.
Follow Venus Remedies in your weekly email
Every Wednesday you see whether Venus Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology.
Show more
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
Stock analysis
Venus Remedies Limited (VENUSREM) currently trades at ₹1,797, while our model-based Fair Value estimate is ₹1,976, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹1,307 per share, and 1 of the 24 models we run sit above the ₹1,797 price.
Bear case: the Asset-Based group reads lowest at ₹332.69, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹1,310 (bear) to ₹2,674 (bull), the price of ₹1,797 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Venus Remedies Limited reported revenue of ₹7.7B in FY2026 versus ₹6.0B in FY2022, a compound +6.5%/yr. Reported net income was ₹1.0B in FY2026, compounding +26.0%/yr from FY2022.
Key figures
Market cap ₹24.0B (≈ $249M) · P/E ratio 19.7 · P/S ratio 2.63 · EPS (TTM) ₹91.24 · Net margin 13.4% · Return on equity 16.8% · Return on assets (EBIT) 6.9% · Operating margin 15.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 314% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 10%, VENUSREM screens cheaper than that median.
Fair Value models
Bear ₹1,310Fair Value ₹1,976Bull ₹2,674
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹46.24 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+18.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Start year 2021 (pandemic). Over 10 years: +6.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.13.8% vs 32.8%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 16%
2026 sits 261% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +13.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (TTM)16.8% · Top 25%
Return on assets9.7% · Top 25%
Net margin (TTM)14.3% · Top 25%
Operating margin (TTM)15.3% · Above median
Growth and dividend
Revenue growth35.6% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Venus Remedies Limited (VENUSREM) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹1,976 versus a price of ₹1,797, about +10% upside (undervalued).
What is the fair value of VENUSREM?
Our model-based fair value for Venus Remedies Limited is ₹1,976 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹1,797.
What is the quality score of VENUSREM?
Venus Remedies Limited has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Venus Remedies Limited (VENUSREM)?
Our model-based price target is the fair value of ₹1,976 (as of Oct 1, 2026) from 24 valuation models. Cautious scenario ₹1,310, optimistic scenario ₹2,674. It is a calculation from audited fundamentals, not an analyst target.
What is the Venus Remedies Limited stock forecast for 2026?
Our models put fair value at ₹1,976, about +10% upside versus a price of ₹1,797 (undervalued). Cautious scenario ₹1,310, optimistic scenario ₹2,674. The calculation is refreshed regularly with new filings.
What is the revenue of Venus Remedies Limited (VENUSREM)?
Venus Remedies Limited reported trailing-twelve-month revenue of about ₹8.1B (latest available figure, as of Oct 1, 2026).
What growth is priced into Venus Remedies Limited (VENUSREM)?
For today's price to be fair in a discounted-cash-flow model, Venus Remedies Limited would have to grow free cash flow by +18.1 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.0 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of VENUSREM use?
Our models discount Venus Remedies Limited at 13.9 %: a base by market capitalisation (micro), damped by beta 0.35, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Venus Remedies Limited that is +18.1 % per year a year over ten years, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Venus Remedies Limited (VENUSREM) delivered so far?
Over the past 5 years revenue at Venus Remedies Limited grew +7.0 % a year. The price currently implies +18.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Venus Remedies Limited (VENUSREM) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into Venus Remedies Limited (+18.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Venus Remedies Limited (VENUSREM)?
The free-cash-flow yield on the price is 4.98 %: that much free cash flow Venus Remedies Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Venus Remedies Limited (VENUSREM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Venus Remedies Limited it is ₹1,976 per share (as of Oct 1, 2026), against a price of ₹1,797. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Venus Remedies Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, VENUSREM trades below its calculated fair value: price ₹1,797, fair value ₹1,976, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VENUSREM?
No. The price is what the market pays today (₹1,797); the fair value is what the company's own numbers justify (₹1,976). For Venus Remedies Limited the two are ₹179.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Venus Remedies Limited worth?
The market values Venus Remedies Limited at about ₹24.0B (market capitalisation, as of Oct 1, 2026). Per share that is ₹1,797; our models calculate a fair value of ₹1,976 per share.
What do the bullish and bearish scenarios say about VENUSREM?
Our models span a range for Venus Remedies Limited: cautious scenario ₹1,310, base ₹1,976, optimistic ₹2,674 per share (as of Oct 1, 2026, price ₹1,797). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VENUSREM?
Venus Remedies Limited trades at a price-to-earnings ratio of 19.7 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,976 is built from several models across several years. Other multiples: P/B 3.6, P/S 3.0, EV/EBITDA 14.2.
How solid is the balance sheet of Venus Remedies Limited (VENUSREM)?
Balance-sheet figures for Venus Remedies Limited (as of Oct 1, 2026): return on equity 16.8%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is VENUSREM from its 52-week high?
Venus Remedies Limited trades at ₹1,797, about 8% below its 52-week high of ₹1,947 and 314% above the low of ₹434.35 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,976 is for.
Which stocks are comparable to Venus Remedies Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Venus Remedies Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹1,797, calculated fair value ₹1,976 (+10%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VENUSREM calculated?
We run Venus Remedies Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1,976, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Venus Remedies Limited currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Venus Remedies Limited (VENUSREM)?
The closing price on Oct 1, 2026 was ₹1,797. Our model-based fair value is ₹1,976, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Venus Remedies Limited right now?
A fairly wide model range (₹1,310 to ₹2,674) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Venus Remedies Limited
How large is the market capitalisation of Venus Remedies Limited (VENUSREM)?
The market capitalisation of Venus Remedies Limited is ₹24.0B (≈ $249M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Venus Remedies Limited (VENUSREM)?
The price-to-sales ratio of Venus Remedies Limited is 2.63 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Venus Remedies Limited (VENUSREM)?
Earnings per share at Venus Remedies Limited are ₹91.24 (price ÷ EPS = P/E 19.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Venus Remedies Limited (VENUSREM)?
The net margin of Venus Remedies Limited is 13.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Venus Remedies Limited (VENUSREM)?
The return on equity (ROE) of Venus Remedies Limited is 16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Venus Remedies Limited (VENUSREM)?
On an EBIT basis the return on assets of Venus Remedies Limited is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Venus Remedies Limited (VENUSREM)?
The operating margin of Venus Remedies Limited is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Venus Remedies Limited (VENUSREM)?
Revenue at Venus Remedies Limited is growing +35.6% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Venus Remedies Limited (VENUSREM)?
Earnings per share at Venus Remedies Limited are growing +139% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Venus Remedies Limited (VENUSREM) hold?
Venus Remedies Limited holds more cash than debt, ₹182M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Venus Remedies Limited in the live analysis
One click puts Venus Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
